Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

First Published: 10/7/2008


1.		Phase III Randomized Study of Fludarabine Phosphate, Cyclophosphamide, and Rituximab Versus Bendamustine Hydrochloride and Rituximab in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				GCLLSG-CLL10 CLL10, EUDRACT-2007-007587-21, EU-20883, ROCHE-GCLLSG-CLL10, NCT00769522


2.		Bendamustine in Acute Leukemia and MDS

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				16 and over				Other, Pharmaceutical / Industry				2007-0634 NCT00790855


3.		Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 70				Other				Haema CBF SCLC UK/AS 02 NCT00168922

Last Modified: 2/20/2008 First Published: 12/22/2005


4.		Phase II Study of Bendamustine and Rituximab in Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				GCLLSG-CLL2M EU-20552, EUDRACT-2005-001596-34, ROCHE-GCLLSG-CLL2M, NCT00274989


5.		Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				OSHO #73 NCT00385125


6.		A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				C05011 NCT00636792


7.		Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				08-041 NCT00705250


8.		Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				65 and over				Other				08-LEUK-07-MCC/CI NCT00758693

First Published: 1/14/2009


9.		Phase II Study of Bendamustine Hydrochloride in Patients With Recurrent or Progressive Anaplastic Glioma or Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				UWCC-6803 UWCC-6803, FHCRC-6803, IR-6803


10.		A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				20 to 75				Pharmaceutical / Industry				2008002 NCT00794638

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute